Halozyme Therapeutics, Inc. (HALO) is a publicly traded Healthcare sector company. As of May 21, 2026, HALO trades at $69.47 with a market cap of $8.00B and a P/E ratio of 23.31. HALO moved +0.36% today. Year to date, HALO is -3.12%; over the trailing twelve months it is +29.06%. Its 52-week range spans $42.01 to $82.22. Analyst consensus is strong buy with an average price target of $84.48. Rallies surfaces HALO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Halozyme Reports Flat Q1 Revenues and Wider Loss; ENHANZE Deals Progress: Halozyme Therapeutics released its first-quarter earnings snapshot, noting stable revenues and a deeper operating loss driven by elevated R&D spending. The update highlighted ongoing ENHANZE platform partnerships and reaffirmed pipeline progression targets for the remainder of 2026.
| Metric | Value |
|---|---|
| Price | $69.47 |
| Market Cap | $8.00B |
| P/E Ratio | 23.31 |
| EPS | $2.96 |
| Dividend Yield | 0.00% |
| 52-Week High | $82.22 |
| 52-Week Low | $42.01 |
| Volume | 266 |
| Avg Volume | 0 |
| Revenue (TTM) | $1.51B |
| Net Income | $348.84M |
| Gross Margin | 82.79% |
5 analysts cover HALO: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $84.48.